458 related articles for article (PubMed ID: 24236684)
1. 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness.
Xing M; Kokabi N; Camacho JC; Kooby DA; El-Rayes BF; Kim HS
J Comp Eff Res; 2013 Jul; 2(4):435-44. PubMed ID: 24236684
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma.
Rostambeigi N; Dekarske AS; Austin EE; Golzarian J; Cressman EN
J Vasc Interv Radiol; 2014 Jul; 25(7):1075-84. PubMed ID: 24861664
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
4. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
Trials; 2012 Aug; 13():144. PubMed ID: 22913492
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus
Ludwig JM; Zhang D; Xing M; Kim HS
Eur Radiol; 2017 May; 27(5):2031-2041. PubMed ID: 27562480
[TBL] [Abstract][Full Text] [Related]
6. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma.
Kooby DA; Egnatashvili V; Srinivasan S; Chamsuddin A; Delman KA; Kauh J; Staley CA; Kim HS
J Vasc Interv Radiol; 2010 Feb; 21(2):224-30. PubMed ID: 20022765
[TBL] [Abstract][Full Text] [Related]
7. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.
Salem R; Lewandowski RJ; Kulik L; Wang E; Riaz A; Ryu RK; Sato KT; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Ibrahim SM; Senthilnathan S; Baker T; Gates VL; Atassi B; Newman S; Memon K; Chen R; Vogelzang RL; Nemcek AA; Resnick SA; Chrisman HB; Carr J; Omary RA; Abecassis M; Benson AB; Mulcahy MF
Gastroenterology; 2011 Feb; 140(2):497-507.e2. PubMed ID: 21044630
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma.
Lance C; McLennan G; Obuchowski N; Cheah G; Levitin A; Sands M; Spain J; Srinivas S; Shrikanthan S; Aucejo FN; Kim R; Menon KV
J Vasc Interv Radiol; 2011 Dec; 22(12):1697-705. PubMed ID: 21983055
[TBL] [Abstract][Full Text] [Related]
9. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
Trials; 2014 Dec; 15():474. PubMed ID: 25472660
[TBL] [Abstract][Full Text] [Related]
10. Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study.
Huang YH; Park BV; Chen YF; Gaba RC; Guzman G; Lokken RP
J Vasc Interv Radiol; 2019 Sep; 30(9):1317-1324. PubMed ID: 31375450
[TBL] [Abstract][Full Text] [Related]
11. (90)Y-glass microspheres for hepatic neoplasia.
Mahnken AH
Future Oncol; 2015; 11(9):1343-54. PubMed ID: 25952780
[TBL] [Abstract][Full Text] [Related]
12. Transarterial chemoembolization and yittrium-90 for liver cancer and other lesions.
Minocha J; Salem R; Lewandowski RJ
Clin Liver Dis; 2014 Nov; 18(4):877-90. PubMed ID: 25438288
[TBL] [Abstract][Full Text] [Related]
13. Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?
Meza-Junco J; Montano-Loza AJ; Liu DM; Sawyer MB; Bain VG; Ma M; Owen R
Cancer Treat Rev; 2012 Feb; 38(1):54-62. PubMed ID: 21726960
[TBL] [Abstract][Full Text] [Related]
14. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
[TBL] [Abstract][Full Text] [Related]
15. Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease.
Fidelman N; Kerlan RK
AJR Am J Roentgenol; 2015 Oct; 205(4):742-52. PubMed ID: 26397322
[TBL] [Abstract][Full Text] [Related]
16. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival.
Hilgard P; Hamami M; Fouly AE; Scherag A; Müller S; Ertle J; Heusner T; Cicinnati VR; Paul A; Bockisch A; Gerken G; Antoch G
Hepatology; 2010 Nov; 52(5):1741-9. PubMed ID: 21038413
[TBL] [Abstract][Full Text] [Related]
17. Transarterial chemoembolization and radioembolization.
Sangro B; Salem R
Semin Liver Dis; 2014 Nov; 34(4):435-43. PubMed ID: 25369305
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma.
Lee EW; Khan S
Clin Mol Hepatol; 2017 Dec; 23(4):265-272. PubMed ID: 29113030
[TBL] [Abstract][Full Text] [Related]
19. Intra-arterial therapies for unresectable and chemorefractory colorectal cancer liver metastases: a systematic review and meta-analysis.
Levy J; Zuckerman J; Garfinkle R; Acuna SA; Touchette J; Vanounou T; Pelletier JS
HPB (Oxford); 2018 Oct; 20(10):905-915. PubMed ID: 29887263
[TBL] [Abstract][Full Text] [Related]
20. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
